ArticleCureus2026
Prognostic Factors and Survival Outcomes in Pediatric Acute Lymphoblastic Leukemia: A Real-World Retrospective Cohort Study from a Tertiary Care Center in North India.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with outcomes varying significantly across different populations. While survival rates have significantly improved in high-income countries, data from low- and middle-income countries (LMICs) remain heterogeneous. The Kashmir region in India represents a unique population with distinct genetic and demographic characteristics, including high rates of consanguinity and potential pharmacogenomic variability. This study aimed to evaluate the prognostic significance of clinical and biological factors and their impact on survival outcomes in pediatric ALL patients treated in a real-world tertiary care setting. Methods This retrospective cohort study included pediatric patients (aged 1-18 years) diagnosed with ALL between June 2016 and November 2023 at the State Cancer Institute, Sher-i-Kashmir Institute of Medical Sciences, Srinagar, Jammu & Kashmir, India. All patients were treated according to the Berlin-Frankfurt-Münster (BFM)-95 pediatric ALL protocol with risk stratification based on clinical parameters, cytogenetics, and early treatment response. Key prognostic variables included age, gender, leukocyte count at presentation, immunophenotype, cytogenetics, Day 8 prednisolone response, and Day 33 bone marrow and minimal residual disease (MRD) status post induction. Survival outcomes were assessed using Kaplan-Meier analysis, and prognostic factors were evaluated using univariate and multivariate Cox regression models. Results A total of 232 patients were analyzed after exclusions. The median age was 8.5 years, with a male predominance (58.2%, n=135). B-cell ALL constituted (84.9%, n=197) of cases. A good prednisolone response on Day 8 was observed in 96.6% (n=224) of patients. On day 33, 89.7% (n=208) achieved bone marrow remission and 82.8% (n=192) attained MRD negativity. After a median follow-up of 49 months, 43 patients (18.5%) relapsed, and 56 patients (24.1%) died. The estimated five-year overall survival (OS) and event-free survival (EFS) were 74.5% and 66.9%, respectively. On univariate analysis, favorable prognostic factors included younger age, B-cell phenotype, absence of high-risk cytogenetics, MRD negativity, and marrow remission at Day 33. On multivariate analysis,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.